Coverage for the indication versus for the drug — setting out what I have, and where I think it stops being reliable.
The question about coverage that I actually want answered is the second one below. The first is context and I have kept it short.
Both are stated with units, and I have said what I already checked so that nobody repeats it.
The strongest argument against my own position on coverage, stated as well as I can state it, since nobody else has yet.
Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves surprise at the pharmacy.
That has been true for the cases I have seen and I have not seen many.
Coverage sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.
Post #7 answers the question as asked. The question underneath it is different.
An honest declaration on coverage: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
Keep every document with dates in one place. An appeal months later is assembled from whatever you kept.
Where I would push back on the coverage consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves frustration.
Nothing here is legal or medical advice, and appeal processes differ enough by jurisdiction and payer that specifics do not transfer.
Coverage for weight management versus diabetes: many formularies cover these compounds for type 2 diabetes but not for weight management. The indication matters and appeals based on the covered indication work better.
The number is defensible. The precision I gave it is not.
Worth separating two things that post #14 runs together.
Second-hand on coverage, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
Keep every document with dates in one place. An appeal months later is assembled from whatever you kept.
On coverage I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.
Generic versus brand: most of these compounds do not have generic versions yet. Once they do, formulary coverage and pricing will shift.
The conclusion is tentative; the arithmetic underneath it is not.
Nothing here is legal or medical advice, and appeal processes differ enough by jurisdiction and payer that specifics do not transfer.
Second-hand, so weight it accordingly.
Post #23 answers the question as asked. The question underneath it is different.
Coverage for the device and for the compound can be decided separately, which surprises people at the pharmacy counter.
Scoping that to what I have actually seen rather than what I have read.
The version of coverage that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves frustration.
Where coverage was granted, saying what the successful submission contained is one of the more useful posts on the site.